Jeffrey Rosenfeld, Ph.D. has extensive experience in genomics and bioinformatics. Over his 15-year career in genomics, he has worked on a wide range of biological and genetic projects including
DeciBio Analytics has launched three 2021 DxBooks databases, covering U.S. labs’ testing behaviors in the areas of oncology biomarkers, infectious disease diagnostics, and SARS-CoV-2 testing. These databases, purchased in 2019
DeciBio’s Spatial Omics Q&A with Ben Hindson, CSO for 10x Genomics
On February 24th, 10x Genomics hosted their first Xperience event, which showcased the next wave of innovations for their three product verticals: Chromium, Visium, and the upcoming in situ
Spatial Omics Year in Review (2020): Transcriptomics Takes Center Stage
While most industries slowed down in response to the global pandemic in 2020, the field of spatial omics certainly did not. Established companies and startups continued to announce products,
Update on the Adoption And Utilization of Emerging Precision Medicine Biomarkers and Technologies in Routine Clinical Care
At DeciBio Consulting, our mission is to provide market intelligence and insights to advance precision medicine. To this end, we track this space closely, especially the field of precision oncology,
DeciBio’s Q&A with Brady Davis, SVP of Business Development for Canexia Health
DeciBio had the pleasure of interviewing Canexia Health’s SVP of Business Development, Brady Davis. We interviewed Brady to understand how Canexia Health and Project ACTT (Access to Testing and
DeciBio’s Q&A with Ramon Felciano, Ph.D., CTO & VP of Strategy for QIAGEN Digital Insights
Hey Ramon, thanks for joining us for this interview today. Could you share some background to help our readers get to know you and understand how you see your role
DxBooks Data Insights: Why Large-Scale Antibody Testing Remains Out of Reach
With its ability to quantify past infections and potential to measure population-level immunity, serology testing adds an attractive tool to the COVID-fighting toolkit. While the initial burst of test
DxBooks Data Insights: Supply-Chain Constraints Hinder Diagnostic Testing Capabilities
Months into the COVID-19 pandemic, U.S. testing capacity continues to lag behind its goals. The Harvard Global Institute estimated that the U.S should have at least 900,000 SARS-CoV-2 tests